Recruiting Advanced Solid Tumors Studies in Salt Lake City
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors....
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid...
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2RĪ± Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be adminis...
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor acti...
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors....
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, a...
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: * Hepatoblastoma is a common liver cancer in babies and very y...
About Advanced Solid Tumors Clinical Trials in Salt Lake City
Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.
There are currently 7 advanced solid tumors clinical trials recruiting participants in Salt Lake City, UT. These studies are seeking a combined 1,453 participants. Research is being sponsored by Daiichi Sankyo, Nuvation Bio Inc., Aulos Bioscience, Inc. and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Advanced Solid Tumors Clinical Trials in Salt Lake City ā FAQ
Are there advanced solid tumors clinical trials in Salt Lake City?
Yes, there are 7 advanced solid tumors clinical trials currently recruiting in Salt Lake City, UT. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Salt Lake City?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Salt Lake City research site will contact you about next steps.
Are clinical trials in Salt Lake City free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Salt Lake City studies also compensate for your time and travel.
What advanced solid tumors treatments are being tested?
The 7 active trials in Salt Lake City are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.
Data updated March 2, 2026 from ClinicalTrials.gov